reports
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal...
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k) submission BRAINTREE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces that it has received the U.S. Food and Drug Administration’s (“FDA”) approval to proceed with its pivotal h...
Bezeq The Israel Telecomunication Corp Ltd: 1 director
A director at Bezeq The Israel Telecomunication Corp Ltd bought 990,947 shares at 4.470ILS and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
Egyptian For Tourism Resorts: 1 director
A director at Egyptian For Tourism Resorts bought 3,585,000 shares at 0.000EGP and the significance rating of the trade was 92/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
United Energy Group Ltd: 1 director
A director at United Energy Group Ltd sold 58,000,000 shares at 0.630HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Misr Fertilizers Production Company (Mopco): 1 director
A director at Misr Fertilizers Production Company (Mopco) bought/sold 25,827,193 shares at 0.000EGP and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
Kumho Electric : 1 director
A director at Kumho Electric sold 120,000 shares at 800.000KRW and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Indberetning af ledende medarbejders og disses nærtståendes transaktio...
Indberetning af ledende medarbejders og disses nærtståendes transaktioner med ROCKWOOL A/S aktier Selskabsmeddelelsefor ROCKWOOL A/SMeddelelse nr. 30 – 2024til Nasdaq Copenhagen 3. juni 2024 Indberetning af ledende medarbejders og disses nærtståendes transaktioner med ROCKWOOL A/S aktier ROCKWOOL A/S har i henhold til markedsmisbrugsforordningens art. 19 (forordning (EU) nr. 596/2014) modtaget nedenstående indberetninger fra bestyrelsesmedlemmer og ledende medarbejdere og disses nærtståendes transaktioner med ROCKWOOOL A/S aktier. 1 Nærmere oplysninger om personen med ledelsesan...
Report on transactions of executives and related parties in ROCKWOOL A...
Report on transactions of executives and related parties in ROCKWOOL A/S shares Company announcementfor ROCKWOOL A/SRelease no. 30 – 2024to Nasdaq Copenhagen 3 June 2024 Report on transactions of executives and related parties in ROCKWOOL A/S shares ROCKWOOL A/S has received and hereby provides notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in ROCKWOOL A/S made by persons discharging managerial responsibilities and/or persons closely related with them. 1 Details of the person discharging managerial responsibilities...
Autonomix Announces Approval of Protocol Amendment by Ethics Committee...
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has received Ethics Committee approval of the protocol amendment for its ongoing proof-of-c...
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. Provides Interim Update Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases. AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or “ETBs”) fo...
Maris-Tech Receives New Order for $225,000 From a Military Drone Manuf...
Maris-Tech Receives New Order for $225,000 From a Military Drone Manufacturer for a Unique Solution for Unmanned Aircraft Systems The advanced video payload for drones will be based on Maris-Tech’s Uranus technology Rehovot, Israel, June 03, 2024 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK) ("Maris-Tech" or the "Company"), a B2B provider of edge computing artificial intelligence (“AI”) accelerated video solutions for edge platforms, today announced that it has received an order for $225,000 from Aero Sol, a leading military drone manufacturer, for a new video payload solution ...
Coherent Appoints Jim Anderson as Chief Executive Officer
Coherent Appoints Jim Anderson as Chief Executive Officer PITTSBURGH, June 03, 2024 (GLOBE NEWSWIRE) -- Coherent Corp. (the “Company” or “Coherent”) (NYSE: COHR), a global leader in materials, networking, and lasers, today announced that following a comprehensive search, its Board of Directors has appointed Jim Anderson, an established industry executive with a proven track record of driving innovation and leading business transformations, as the Company’s new Chief Executive Officer, effective today. Mr. Anderson also joins the Company’s Board of Directors. Mr. Anderson joins Coherent...
EQS-News: Mainz Biomed präsentierte branchenführende Ergebnisse seiner...
Emittent / Herausgeber: Mainz BioMed N.V. / Schlagwort(e): Studienergebnisse/Konferenz Mainz Biomed präsentierte branchenführende Ergebnisse seiner gepoolten Studie auf dem ASCO 2024 03.06.2024 / 14:01 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Mainz Biomed präsentierte branchenführende Ergebnisse seiner gepoolten Studie auf dem ASCO 2024 Die neuen Daten bestätigen die Ergebnisse der ColoFuture- und eAArly-DETECT-Studien mit einer Sensitivität von 92% für Darmkrebs und 82% für fortgeschrittene Adenome, sowie 95,8% für die Erkenn...
EQS-News: Mainz Biomed Presented Industry Leading Results of its Poole...
Issuer: Mainz BioMed N.V. / Key word(s): Study results/Conference Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 03.06.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecu...
InnovAge PACE Recertified as a Great Place to Work
InnovAge PACE Recertified as a Great Place to Work PACE Program Provides Highly Coordinated, Personalized Senior Care DENVER, June 03, 2024 (GLOBE NEWSWIRE) -- (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE) has been recertified as a Great Place to Work. “Earning this badge of honor is a reflection of the strength, credibility, and camaraderie of the InnovAge team,” says InnovAge President and CEO Patrick Blair. “All of us are driven ...
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK C...
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic...
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Co...
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m. The fireside chat will be webcasted and available under “...
Mainz Biomed Presented Industry Leading Results of its Pooled Study at...
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed’s mRNA biomarkers to detect CRC and precancerous lesions BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagno...
Medicenna Reports Significant Survival Benefit in Patients with Recurr...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL-4 receptor (IL-4R) expression in unresectable recurrent glioblastoma (rGBM) patients in the Phase 2b Study Biz...
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for M...
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseasesDNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potential for clinical benefit for a rare neurodegenerative disease and the drug sponsor’s ability to advance development tow...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.